2024-09-15 - Analysis Report
## JNJ Stock Analysis Report

**Company Overview:** Johnson & Johnson is a multinational pharmaceutical, medical device, and consumer packaged goods conglomerate. 

**1. Performance Comparison:**

* **JNJ's Cumulative Return:** 18.89%
* **S&P 500 (VOO) Cumulative Return:** 87.74%
* **Performance Gap:** -68.85% (Relative Gap: 13.93%)

JNJ has significantly underperformed the S&P 500 over the measured period.  It has been lagging behind the market, but the relative gap suggests that its performance is within the historical range of its performance compared to the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** 164.64
* **5-day Moving Average:** 165.57
* **20-day Moving Average:** 163.75
* **60-day Moving Average:** 156.8

The price is currently slightly below the 5-day moving average, suggesting a short-term downward trend. However, it is above the 20-day and 60-day moving averages, indicating potential for continued upward movement.

**3. Technical Indicators:**

* **RSI:** 56.72
* **PPO:** -0.17
* **Delta_Previous_Relative_Divergence:** -0.31 (Short-term decline)
* **Expected Return:** 11.82% (Maximum expected return over 5 years for current investment)

The RSI suggests the stock is in neutral territory, neither overbought nor oversold. The PPO suggests a slight downward trend, aligning with the Delta_Previous_Relative_Divergence. However, the expected return suggests potential upside for long-term investors.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |
| 2024-02-16 | 10.32 | 21.35 B$ |

The latest earnings report for Q2 2024 was released on 2024-07-25. The company reported EPS of $1.95, exceeding the analysts' estimates of $1.91. The company also beat revenue estimates, reporting $22.45 billion compared to the expected $22.37 billion.

**5. Overall Analysis:**

JNJ's recent performance has been underwhelming compared to the broader market. While it has faced some headwinds, its recent earnings beat suggests a healthy financial outlook. Technical indicators point to a potential short-term decline but long-term prospects remain positive, especially considering the expected return.

**6. Investment Recommendation:**

While JNJ has not been performing as well as the S&P 500, its strong earnings and long-term growth potential make it a worthwhile investment for long-term investors. Consider adding JNJ to a diversified portfolio with a long-term investment horizon. However, short-term investors might want to wait for more bullish signals before entering a position. 
